Emerging Therapeutic Options for the Management of COPD. Issue 7 (January 2013)

• Record Type: Journal Article
• Authors: Reid, Debra J.; Pham, Nga T.
• Is Part Of: Clinical medicine insights. Issue 7(2013)
• Publication Date: 2013-01
• Subjects: chronic obstructive pulmonary disease -- COPD therapy -- long-acting muscarinic agent -- phosphodiesterase-4 inhibitor -- long-acting β2-agonist; Cardiovascular system -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Periodicals; Blood Circulation; Respiration; Lung Diseases; Cardiovascular system -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; Periodicals; 616.1005
• DOI: 10.4137/CCRPM.S8140
• Languages: English
• ISSNs: 1179-5484

Abstract

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.